NCT03881852View on ClinicalTrials.gov

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

November 27, 2019

Study Completion Date

November 27, 2019

Conditions
NarcolepsyCataplexy NarcolepsyExcessive Sleepiness
Interventions
DRUG

AXS-12 (Reboxetine)

Dosed orally, twice daily for up to 3 weeks

DRUG

Placebo

Dosed orally, twice daily for up to 3 weeks

Trial Locations (14)

10467

CONCERT Study Site, The Bronx

20815

CONCERT Study Site, Chevy Chase

29201

CONCERT Study Site, Columbia

30501

CONCERT Study Site, Gainesville

33126

CONCERT Study Site, Miami

33707

CONCERT Study Site, St. Petersburg

35213

CONCERT Study Site, Birmingham

45219

CONCERT Study Site, Cincinnati

46804

CONCERT Study Site, Fort Wayne

78229

CONCERT Study Site, San Antonio

78731

CONCERT Study Site, Austin

80301

CONCERT Study Site, Boulder

92705

CONCERT Study Site, Santa Ana

94501

CONCERT Study Site, Alameda

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY